share_log

Nexalin Technology Awarded Key Patent Related To Gen-3 HALO Clarity

Benzinga ·  Apr 5 01:12

Mark White, CEO of Nexalin Technology, stated, "This method of use patent award marks a major achievement for the Company and follows another recent patent covering our core technology. These patents extend through 2040 and are a critical element of our overall strategy, given the mounting clinical data supporting the benefits of our noninvasive, deep frequency brain stimulation technology in the fields of insomnia, depression, and anxiety. A key differentiator for our new Gen-3 HALO Clarity is that, for the first time, it enables patients to receive this treatment in the privacy of their own homes with remote monitoring by a physician in Nexalin's Virtual Clinic."

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment